Cognitive Improvement is Correlated with Increased Dynamic Functional Connectivity of Default Mode Network by Personalized rTMS in Alzheimer's Disease

Lili Wei
Zhejiang University School of Medicine Sir Run Run Shaw Hospital

Jintao Wang
Zhejiang University School of Medicine Sir Run Run Shaw Hospital

Yingchun Zhang
Zhejiang University School of Medicine Sir Run Run Shaw Hospital

Luoyi Xu
Zhejiang University School of Medicine Sir Run Run Shaw Hospital

Kehua Yang
Zhejiang University School of Medicine Sir Run Run Shaw Hospital

Xinghui Lv
Zhejiang University School of Medicine Sir Run Run Shaw Hospital

Zhenwei Zhu
Zhejiang University School of Medicine Sir Run Run Shaw Hospital

Qian Gong
Zhejiang University School of Medicine Sir Run Run Shaw Hospital

Weiming Hu
third People's Hospital of Quzhou

Xia Li
Shanghai Mental Health Center

Mincai Qian
Huzhou Third People's Hospital

Yuedi Shen
Hangzhou Normal University

Wei Chen (✉ smcw@zju.edu.cn)
Zhejiang University School of Medicine Sir Run Run Shaw Hospital  https://orcid.org/0000-0003-0903-7945
Keywords: repetitive transcranial magnetic stimulation, Alzheimer's disease, default mode network, functional magnetic resonance imaging, parietal lobe, hippocampus

DOI: https://doi.org/10.21203/rs.3.rs-554187/v1

License: ☺️ ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Cognitive Improvement is Correlated with Increased Dynamic Functional Connectivity of Default Mode Network by Personalized rTMS in Alzheimer's disease

Lili Wei, Jintao Wang, Yingchun Zhang, Luoyi Xu, Kehua Yang, Xinghui Lv, Zhenwei Zhu, Qian Gong, Weiming Hu, Xia Li, Mincai Qian, Yuedi Shen, Wei Chen

These authors contributed equally to this work.

1 Department of psychiatry, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China
2 Third People’s Hospital of Quzhou, Quzhou, Zhejiang, China
3 Shanghai Mental Health Center, Shanghai, China
4 Third People’s Hospital of Huzhou, Huzhou, Zhejiang, China
5 Hangzhou Normal University Medical School, Hangzhou, Zhejiang, China
6 Department of Psychology and Behavioral Sciences, Zhejiang University, Hangzhou, China
7 Key Laboratory of Medical Neurobiology of Zhejiang Province, Hangzhou, China

Correspondence to: Wei Chen
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
East Qingchun Road 3#, Hangzhou, Zhejiang, China
Correspondence may also be addressed to:

Yuedi Shen
Hangzhou Normal University Medical School, Hangzhou, Zhejiang, China
E-mail: shenyd5@126.com

Mincai Qian
Third People’s Hospital of Huzhou, Huzhou, Zhejiang, China
E-mail: 1311956613@qq.com
Abstract

**Background:** Repetitive transcranial magnetic stimulation (rTMS) is thought to be a promising therapeutic approach for Alzheimer's disease patients.

**Methods:** In the present report, a double-blind, randomized, sham-controlled rTMS trial was conducted in mild-to-moderate Alzheimer's disease patients. High-frequency rTMS was delivered to a subject-specific left lateral parietal region that demonstrated highest functional connectivity with the hippocampus using resting-state fMRI. The Mini Mental State Examination (MMSE) and Philadelphia Verbal Learning Test (PVLT) were used to evaluate patients’ cognitive functions.

**Results:** Patients receiving active rTMS treatment (n=31) showed a significant increase in the MMSE, PVLT-Immediate recall, and PVLT-Short Delay recall scores after two weeks of rTMS treatment, whereas patients who received sham rTMS (n=27) did not show significant changes in these measures. Dynamic functional connectivity (dFC) magnitude of the default mode network (DMN) in the active-rTMS group showed a significant increase after two weeks of rTMS treatment, and no significant changes were found in the sham-rTMS group. There was a significantly positive correlation between changes of the MMSE and changes of the dFC magnitude of DMN in the active-rTMS group, but not the sham-rTMS group.

**Conclusions:** Our findings are novel in demonstrating the feasibility and effectiveness of the fMRI-guided rTMS treatment in Alzheimer's disease patients, and DMN might play a vital role in therapeutic effectiveness of rTMS in Alzheimer’s disease.
Trial registration: China National Medical Research Platform (http://114.255.48.20/login, No:MR-33-20-004217), retrospectively registered 2020-12-23.

Keywords

repetitive transcranial magnetic stimulation; Alzheimer's disease; default mode network; functional magnetic resonance imaging; parietal lobe; hippocampus
Background

Alzheimer's disease is a highly prevalent brain disorder that is predicted to affect more than 100 million people by the year 2050[1]. It has tremendous social and economic impact worldwide. Pharmacological regimen has so far dominated the clinical practice in treating Alzheimer’s disease. In recent years, repetitive transcranial magnetic stimulation (rTMS) therapy has been considered to be a promising treatment protocol for psychiatric and neurological disorders [2-4], including mild cognitive impairment (MCI) and Alzheimer's disease [5-8]. Previous studies have demonstrated that rTMS improves language performance [9-11], attentional capacity [12], executive function [13-15], verbal memory and episodic memory [16-19]. Despite its therapeutic effectiveness, there is no consensus on the most effective target region for clinical treatment of Alzheimer’s disease with rTMS, with varying spatial regions in different studies, including dorsolateral prefrontal cortex (DLPFC) [9,20], inferior frontal gyrus [12,13], precuneus [21], and posterior temporal gyrus [16]. Moreover, neurophysiological mechanism underlying rTMS on Alzheimer’s disease treatment is unclear [22-24]. This knowledge gap hinders faster application of rTMS in Alzheimer’s disease.

Alzheimer's disease is a neurodegenerative disease that affects the functional connections of the brain, which can be proven by the default mode network (DMN) changes in Alzheimer’s disease patients [25,26]. Alzheimer's disease patients mainly manifest the reduction of functional connection of DMN, especially the connections between the posterior precuneus, posterior cingulate gyrus and the anterior medial
prefrontal cortex (MPFC), anterior cingulate gyrus; there are also DMN-related left and right hippocampus changes [27-29]. Changes in DMN functional connectivity are related to changes of patients’ cognitive function, and are considered to be a high risk factor of patients to develop dementia [30,31]. After medication, cognitive therapy, and acupuncture treatment, Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), auditory vocabulary and delayed recall will change, and the functional connectivity of DMN increase after treatment in Alzheimer's disease patients [32-34]. In summary, DMN plays an important role in the development and treatment of Alzheimer's disease. Therefore, this network might serve as a promising therapeutic target for Alzheimer’s disease.

In the present study, we conducted a double-blind, randomized, sham-controlled clinical trial using an functional magnetic resonance imaging (fMRI)-guided rTMS technique [35,36] to treat patients with Alzheimer’s disease. Specifically, therapeutic high-frequency rTMS, which has been demonstrated effective in major depression [37-39], was delivered to an individualized left lateral parietal region that demonstrated highest functional connectivity with the each patient’s hippocampus using resting-state fMRI for two weeks, and several fMRI sessions and a complete neuropsychological battery of tests were administered in this trial. The hypotheses of this study are (1) the cognitive functions of Alzheimer's disease patients can be improved by stimulating a key brain region of DMN (lateral parietal lobule) with the fMRI-guided personalized rTMS technique, and (2) the rTMS-induced cognitive function improvement is correlation with the perturbation of DMN.
Materials and methods

Participants

A total of 103 patients with mild-to-moderate Alzheimer's disease patients were recruited from outpatients and inpatients of the Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China, and underwent a standardized evaluation. The patients were screened from an ongoing follow-up project, which aimed to treat Alzheimer's disease by personalized fMRI-guided rTMS of the parietal lobe. This project has been registered on the China National Medical Research Platform(http://114.255.48.20/login, No:MR-33-20-004217). Patients were included if they (1) met the diagnostic criteria for probable Alzheimer's disease according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition; (2) had a Clinical Dementia Rating (CDR) score between 0.5 and 2; (3) were from fifty-five to eighty-five years old, and right-handed. The exclusion criteria included: (1) severe liver, kidney, heart, lung diseases; (2) history of significant head trauma or neurological disorders; (3) focal brain lesions on T1 or T2 images; (4) any MRI contraindications (e.g., medical implants or devices, metal in the body or claustrophobia). This study was approved by the Ethics Committee of the Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University (No: 20170228-1), and all patients signed an informed consent form.

Procedures
A double-blind, randomized, sham-controlled trial was conducted in patients (The clinicians, neuropsychologists and patients did not know whether the patients received the real or sham treatment, only the rTMS operators knewed the randomized treatment). The active-rTMS group underwent a 2-week real rTMS treatment, while the sham group underwent a 2-week sham treatment. Sessions occurred once daily, 5 days/week. Patients underwent a complete neuropsychological battery of tests and a multimodal MRI scan at baseline (T0), immediately (T1) and 12-week follow-up after the end of rTMS treatment (T2).

Among the 103 patients, before randomization, ten patients were excluded due to the brain lesion and psychiatric disorder, five patients withdrew due to personal reasons, and two patients were not contactable. Finally, eighty-six patients were randomized to either rTMS or sham treatment. A total of fifty-eight patients completed 2-week treatment and assessments including neuropsychological tests and fMRI scan (Eight patients in the rTMS group and nine patients in the sham group did not complete neuropsychological assessments at baseline or rTMS/ sham treatment. Four patients in the rTMS group and seven patients in the sham group did not finish the fMRI scan at T1). Thirty-one of them were assigned to the rTMS group, and twenty-seven were assigned to the sham group. In addition, another nine patients in rTMS group and seven patients in sham group have not completed the 12-week follow-up up to now (four patients in rTMS group and four patients in sham group refused the follow-up, while five patients in rTMS group and three patients in sham group have not reached the follow-up period), but their data of baseline and
immediately after the end of rTMS treatment were kept for analyses.

**MRI data acquisition**

T1-weighted and resting-state fMRI data were acquired using a 3.0 T MR scanner (GE Discovery MR750, GE Medical Systems, Milwaukee, Wisconsin, USA) equipped with an eight-channel head coil array in the Affiliated Hospital of Hangzhou Normal University. During scanning, patients were instructed to keep still in the scanner with their eyes open and not think about anything specific. The functional images were obtained axially using an echo-planar imaging (EPI) sequence with the following parameters: 240 volumes; repetition time (TR) = 2,000 ms; echo time (TE) = 30 ms; flip angle (FA) = 90°; field of view (FOV) = 220 × 220 mm²; matrix = 64 × 64; slice thickness = 3.2 mm with no gap. High-resolution anatomic three-dimensional T1-weighted images were obtained with the following parameters: 176 axial slices; TR = 8.1 ms; TE = 3.1 ms; FA = 8°; FOV = 250 × 250 mm²; matrix = 250 × 250; slice thickness = 1.0 mm with no gap.

**Identification of stimulus target**

The stimulus target of each patient was identified by using personal maps of hippocampal resting-state functional connectivity obtained at the baseline. For each patient, fMRI collected during resting state was used to generate seed-based connectivity maps using a hippocampal target as the seed. We chose the voxel in the middle of the hippocampal body (MNI coordinate x=-24, y=-18, z=-18) as
hippocampal target voxel [35]. The stimulation site was a left lateral parietal location that showed high functional connectivity with the left hippocampal seed.

Functional and structural MRI data were preprocessed using Data Processing Assistant for Resting-State fMRI (DPARSF; http://rfmri.org/DPARSF) [40], which is based on SPM12 software (http://www.fil.ion.ucl.ac.uk/spm) and a Resting-State fMRI Data Analysis Toolkit (REST; www.restfMRI.net) [41]. The preprocessing steps included: slice timing after removing first 10 volumes; realign; motion correction; functional/structural co-registration; segment and affixer regularization according to European; resampling to a resolution of 1.5 mm × 1.5 mm × 1.5mm; normalizing into the standard Montreal Neurological Institute (MNI) space using T1 image unified segmentation; spatial smoothing with a 6-mm full-width-at-half-maximum Gaussian kernel; removing linear trend; and filter at 0.01–0.08 Hz. Finally, the resting-state functional connectivity between the hippocampal target and the entire brain were computed. We identified the local maxima connectivity within a 15 mm radius of the MNI coordinates (x=−47, y=−68, z=+36; area region encompassing the inferior parietal lobule, Brodmann areas 39 and 40), and this local maxima was designated as stimulation target region. This stimulation location was marked in stereotactic space and overlaid onto the structural MRI to provide localization during rTMS.

**rTMS Stimulation**

We applied rTMS treatment at personalized left lateral parietal target, guided by an online neuronavigation system (Brainsight 2, Rogue Research, Montreal, Quebec,
Canada). rTMS was applied to the stimulation location during daily treatment sessions using Magstim Rapid2 stimulator with a 70mm air-cooled figure eight coil (Magstim Company, Whitland, Wales, United Kingdom). The stimulation location was located via the structural MRI using a frameless infrared stereotactic system. Motor threshold of each patient was defined as the minimum TMS intensity that evoked a motor evoked potential (MEP) of at least 50 μV for at least 5 of 10 consecutive pulses at baseline. For the stimulation, rTMS was applied at 100%-110% motor threshold to the stimulation location for 20 minutes of consecutive blocks of 10 Hz pulses for two seconds followed by 28 seconds of no stimulation. The TMS coil was held tangential to the scalp of the stimulation location. For the sham stimulation, we rotated the coil by a 45° along the handle axis of the coil and the distance between the stimulation side and the scalp was larger than 5 cm, so that the stimulation side of the coil keep away from the scalp.

**Neuropsychological assessments**

All measurements of neuropsychological assessments were repeated three times: baseline, immediately and 12-week follow-up after the end of rTMS treatment. The trained neuropsychologist, blinded to the randomized treatment, performed the assessments. The main neuropsychological test questionnaire included the Chinese version of Mini Mental State Examination (MMSE), 12-Word Philadelphia Verbal Learning Test (PVLT), CDR, Lawton-Brody Activities of Daily Living (ADL) scale and Patient Health Questionnaire-9 (PHQ-9).
**Neuroimaging Data processing**

Functional and structural MRI data were preprocessed using DPARSF, which is based on SPM12 software. The preprocessing steps included: slice timing after removing first 10 volumes; realign; functional/structural co-registration; normalizing into the standard MNI space using T1 image unified segmentation; resampling to 3-mm isotropic voxels; spatial smoothing with a 6-mm FWHM Gaussian kernel. The preprocessed data were used for the following analyses. Note that a maximum head motion criterion of 3 mm and 3° was applied, and two patients in the active-rTMS group exceeded the criterion, thus their scans were excluded for further analyses.

We concatenated the preprocessed data of all patients to perform group independent component analysis (ICA) using the GIFT toolbox (http://icatb.sourceforge.net ). The number of independent components was estimated as 34 using the minimum description length criteria. The common components were acquired over all participants with ICA decomposition using Infomax algorithm [42], and ICASSO procedure with 10 runs of ICA was used to assure the stability [43]. In the present study, we focused on the DMN, and identified 6 DMN subnetworks based on inspection of their spatial locations and time courses by two trained investigators (J.W. and Y.S.): a DMN subnetwork was selected if it spatially located in canonical DMN regions (including posterior cingulate cortex, medial prefrontal cortex, anterior cingulate cortex, and bilateral parietal lobule) and power spectrum of its associated time course primarily located in the range 0.01-0.1 Hz. The flexible least squares
(FLS) method was applied to calculate the dynamic functional connectivity (dFC) within the DMN for each patient via the dynamic brain connectivity (DynamicBC) toolbox [44]. Specifically, a time-varying parameter regression equation was employed to describe the dynamic interactions between 6 subnetworks of the DMN:

\[ y(t) = x(t) \times \beta(t) + \varepsilon(t) \]

where \( x(t) \) and \( y(t) \) are the time series of two DMN subnetworks, \( \varepsilon(t) \) is the approximation error. The \( \beta(t) \) is the coefficient to estimate the covariance of the two networks and reflects the connectivity between \( x(t) \) and \( y(t) \) at time \( t \). To obtain the \( \beta \) value at each time point, a cost function was defined as:

\[
C(\beta, \varepsilon, T) = \mu \times r_{d}^2(\beta, T) + r_{m}^2(\beta, T)
\]

where \( r_{d}^2(\beta, T) \) is the sum of the squared residual dynamic error \( r_{d}^2(\beta, T) = \sum_{t=1}^{T-1} (\beta(t + 1) - \beta(t))^{T} (\beta(t + 1) - \beta(t)) \) where FLS declares that the coefficients vector evolves slowly over time with \( \beta(t + 1) - \beta(t) \approx 0 \); \( r_{m}^2(\beta, T) \) is the sum of squared residual measurement errors \( r_{m}^2(\beta, T) = \sum_{t=1}^{T} (y(t) - x(t) \times \beta(t))^2 \) that satisfy \( y(t) - x(t) \times \beta(t) \approx 0 \); \( \mu \) is the weighting parameter to control these two parts of the cost function and in the present study, this parameter was set as 100 according to[44]. With FLS, we extracted the time courses of the DMN subnetworks and calculated the dynamic functional connectivity (dFC) magnitude and dFC variance between each pair of the subnetworks. For the inter-network connectivity, dFC magnitude of the DMN was defined as the average of the \( \beta \) values between each pair; the average standard deviation of the \( \beta \) values of all the inter-network pairs was defined as the dFC variance of DMN.
Statistical analysis

The Chi-squared test was performed for the gender and medication distribution, and the independent t-test was used to analyze differences of other continuous variables between the rTMS group and the sham group at baseline. The dFC magnitude, dFC variance, and neuropsychological assessments were analyzed via paired t-tests to evaluate the changes between different time points in each group. Moreover, we performed correlational analysis between changes of the MMSE and changes of the dFC magnitude and variance of the DMN (baseline phase T0 and immediate after treatment phase T1). The analyses were performed using SPSS for Windows (v 20.0, IBM). Two-tailed probability values of p < 0.05 were considered statistically significant for the paired t-test results. For the correlational analysis, the significance level was set as one-tailed p<0.05 since we expected significant correlation in the active-rTMS group.

Results

Patient characteristics

In the present study, there were totally thirty-one patients in rTMS group and twenty-seven patients in sham group for the analyses. As shown in Table 1, statistically significant differences between the treatment and sham groups in baseline characteristics were not found. Specifically, the baseline characteristics include age (p = 0.540), male-to-female ratio (p = 0.792), education level (p = 0.755), medication
rate ($p = 0.829$), MMSE ($p = 0.742$), CDR ($p = 0.796$), ADL ($p = 0.165$), PHQ-9 ($p = 0.594$), PVLT ($p > 0.05$).

**Neuropsychological assessment improvements after rTMS**

The rTMS group showed a significant increase by 1.2 MMSE scores immediate after 2 weeks of rTMS treatment ($p = 0.009$). Whereas, the MMSE scores in the sham group showed no significant increase by 0.6 immediate after 2 weeks of sham treatment ($p = 0.273$). We used the PVLT to further assess memory performance of Alzheimer's disease patients, with higher values indicating greater memory performance. Compared with the sham group, the scores of PVLT Immediate recall ($p < 0.001$) and Short Delay recall ($p = 0.044$) in the treatment group had significant improvement immediate after 2 weeks of rTMS treatment. Nine patients in rTMS group and seven patients in sham group had not completed the 12-week follow-up up to now, there were twenty-two patients in rTMS group and twenty patients in sham group for the 12-week follow-up analyses. Similar to the total sample, the baseline characteristics had no significant differences between groups (Supplementary Table S1). There was no significant improvement on MMSE and PVLT scores in both groups at 12-week follow-up. Performance of both group on the CDR, ADL, PQH-9 and PVLT Long Delay recall did not change significantly. These results showed that 2 weeks of rTMS treatment significantly improved cognitive function in patients of rTMS group compared to the sham group, but the benefits disappeared at 12-week follow-up. Details are shown in Table 2.
Changes of the dFC magnitude of the DMN and correlation results

As shown in Fig. 1A, we identified 6 DMN subnetworks (Fig. S1 in the supplement) with group ICA. The dFC analysis revealed that the dFC magnitude of the DMN in the rTMS group showed a significant increase immediate after 2 weeks of rTMS treatment (p=0.003), and the dFC magnitude then decreased at 12-week follow-up (Fig. 1B). The dFC magnitude of the DMN showed no significant changes in the sham group (Fig. 1B). Across all Alzheimer's disease patients, there was a significantly positive correlation between changes of the MMSE and changes of the DMN dFC magnitude immediate after 2 weeks of rTMS (r=0.291, p=0.015) (Fig. 1C). Moreover, the better improvement in MMSE scores were correlated with the higher dFC magnitude of the DMN in rTMS group (r=0.325, p=0.042), but not in sham group (r=0.207, p=0.151) (Fig. 1C). No significant results were found for the dFC variance measure.

Discussion

In this study, we examined whether the subject-specific hippocampal-targeted rTMS treatment over the lateral parietal lobule could improve the cognitive functions of Alzheimer's disease patients. In the meanwhile, we examined whether this improvement was related to the change of the intra-DMN functional connectivity. After two weeks of rTMS treatment, we found that the active-rTMS group showed a significant increase in the MMSE, PVLT-Immediate recall, PVLT-Short Delay recall
scores and the dFC magnitude of the DMN, whereas the sham-rTMS group did not show significant changes in these measures. Moreover, we found that better improvement in MMSE scores in the active-rTMS group was correlated with more DMN’s dFC magnitude changes.

**Parietal-hippocampal targeted rTMS can improve cognitive function in Alzheimer's disease**

Memory impairment in Alzheimer's disease patients is mainly related to the hippocampus, which is hardly be accessible by the conventional rTMS technique. Prior literature with healthy adult participants has confirmed that memory performance could be enhanced by the subject-specific fMRI-guided rTMS treatment targeted in cortical-hippocampal networks [35,45]. In the present study, we successfully adopted this fMRI-guided rTMS protocol for treating Alzheimer's disease. The active-rTMS group showed a significant increase in MMSE, PVLT Immediate recall and Short Delay recall scores after two weeks of rTMS treatment. The prevalence of depression in Alzheimer's disease may be as high as 50% [46], and even mild depressive symptoms are associated with significant functional impairment. It is important to control for the possibility that patients might benefit from TMS secondary to stimulation effects on comorbid depressive symptoms. It is notable in our results that PHQ-9, which is a validated module for depression in primary care [47,48], did not change significantly. Therefore, the cognitive improvements in the active-rTMS group were not results from alleviating depressive symptoms. Our
results showed that the rTMS-induced cognitive improvement in the active-rTMS group disappeared at 12-week follow-up. It was similar to a recent study [49], which reported that 20Hz rTMS treatment for 30 sessions over six weeks in the DLPFC resulted in a significant improvement in cognition, but this improvement was not maintained in the three-month follow up. rTMS dose and its combination with other therapeutic approaches were important issues in this case. Rabey and Dobronevsky [50] combined rTMS of 1-hour daily session, 5 days per week, for 6 weeks (30 sessions) with cognitive training to treat mild-to-moderate Alzheimer's disease patients, and they found the cognitive improvement lasted for a minimum of 9 months. Our study employed a single treatment modality (i.e., rTMS) and a shorter treatment period (20 minutes daily session, 5 days per week for 2 weeks), therefore potentially have a shorter time of symptomatic improvement. We speculate that the efficacy of rTMS will be consolidated if extended the treatment time or combined with other non-drug treatments such as cognitive stimulation and exercise. The lasting effect of rTMS treatment on Alzheimer’s disease deserves further investigation.

**Parietal-hippocampal targeted rTMS can enhance DMN neural activity in Alzheimer's disease**

In the present study, the dFC magnitude of the DMN was calculated by summarize dynamic functional connectivity strength across all pairs of the six DMN subnetworks, therefore, it can be considered as a measure of the intra-DMN functional connectivity. We found that the dFC magnitude of the DMN in the active-rTMS group
showed a significant increase after two weeks of active rTMS treatment, and better improvement in MMSE scores was correlated with higher DMN’s dFC magnitude change in the active-rTMS group. The dFC magnitude resumed to baseline level at 12-week follow-up, which resembled the trajectory of the cognitive measures. Alzheimer's disease is a generalized disconnection syndrome that causes functional impairments in resting state networks, particularly in DMN [51-53]. Prior literature provided evidence that rTMS improves cognitive performances of Alzheimer's disease patients [54], however there is still a knowledge gap in understanding the neural substrates underlying the therapeutic effectiveness of rTMS in Alzheimer's disease treatment. A study combined rTMS and electroencephalogram techniques [21] found that rTMS treatment on precuneus improved long-term memory in prodromal Alzheimer's disease patients by modulating neural activity of the precuneus and its connections with medial parietal and frontal areas in the DMN. A recent study with fMRI technique [55] demonstrated that rTMS-induced functional connectivity changes within the DMN was associated with clinical cognitive improvements in patients with amnestic MCI. The present study, together with these two studies, highlighted the effectiveness of rTMS in the treatment of Alzheimer's disease patients, and further revealed that intra-DMN functional connectivity might be a neuroimaging substrate for the therapeutic effectiveness of rTMS in the recovery of cognitive impairment in Alzheimer's disease patients.

A major limitation of this study was the relatively heterogeneous Alzheimer's disease sample (0.5≤CDR≤2.0). However, significant differences between the
active-rTMS treatment and sham-rTMS treatment groups in baseline characteristics were not found. Stimulation parameters and study protocol designs varied considerably in previous studies [56], in the present study, we adopted a protocol which has been demonstrated effective in enhancing healthy participants’ memory ability [35]. However, larger trials are essential to determine the optimal parameters in this protocol for its utility in clinical practice, and the findings need to be replicated in studies with larger sample size.

**Conclusions**

In summary, our findings may provide the foundation for a prospective clinical trial. We demonstrated the feasibility and effectiveness of the fMRI-guided rTMS treatment over the lateral parietal lobule in Alzheimer's disease patients, and the neuroimaging results provided evidence that the intra-DMN functional connectivity might be a neural substrate for the therapeutic effectiveness of rTMS in the treatment of Alzheimer's disease patients.

**List of abbreviations**

ADL=Activities of Daily Living scale; CDR=Clinical Dementia Rating; dFC=dynamic Functional Connectivity; DLPFC=Dorsolateral Prefrontal Cortex; DMN=Default Mode Network; MCI=Mild Cognitive Impairment; MMSE=Mini-Mental State Examination; PHQ-9=Patient Health Questionnaire-9; PVLT=12-Word Philadelphia Verbal Learning Test; rTMS=repetitive Transcranial
Appendix A. Supplementary data

Declarations

Ethics approval and consent to participate

This study was approved by the Ethics Committee of the Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University (No: 20170228-1), and all patients signed an informed consent form.

Consent for publication

Written informed consent for publication of their clinical details was obtained from the patient or relative of the patient. A copy of the consent form is available for review by the Editor of this journal.

Availability of data and materials

Data that support the findings of this study are available upon reasonable request.

Competing interests

The authors report no competing interests.

Funding
This work was supported by grant from the National Key Research & Development Program of China (2017YFC1310502), the Natural Science Foundation of China (82071181, 8161101010), and Key Research & Development Program of Zhejiang Province (2020C03021, 2018C03023), and the Science and Technology Program of Hangzhou Municipality (20190101A10).

Authors' contributions

LW contributed to the data collections and data analysis. JW contributed to the neuropsychological assessments and data analysis. YZ, LX, QG, WH and MQ contributed to the data collections. KY and XL contributed to the rTMS treatment. ZZ contributed to the neuropsychological assessments. WC, YS, and XL were responsible for the study concept and design. All authors read and approved the final manuscript.

Acknowledgements

We thank Professor Li Su for assistance in the final preparation of this manuscript.

References

[1] Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011; 10: 819-28.

[2] Fregni F, Pascual-Leone A. Technology insight: noninvasive brain stimulation in neurology-perspectives on the therapeutic potential of rTMS and tDCS. Nat Clin Pract Neurol. 2007; 3: 383-93.
[3] Slotema CW, Blom JD, Hoek HW, Sommer IE. Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. J Clin Psychiatry. 2010; 71: 873-84.

[4] Ni Z, Chen R. Transcranial magnetic stimulation to understand pathophysiology and as potential treatment for neurodegenerative diseases. Transl Neurodegener. 2015; 4: 22.

[5] Nardone R, Bergmann J, Christova M, Caleri F, Tezzon F, Ladurner G, et al. Effect of transcranial brain stimulation for the treatment of Alzheimer disease: a review. Int J Alzheimers Dis. 2012; 2012: 687909.

[6] Chou YH, Ton That V, Sundman M. A systematic review and meta-analysis of rTMS effects on cognitive enhancement in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2020; 86: 1-10.

[7] Koch G, Martorana A, Caltagirone C. Transcranial magnetic stimulation: Emerging biomarkers and novel therapeutics in Alzheimer's disease. Neurosci Lett. 2020; 719: 134355.

[8] Chu CS, Li CT, Brunoni AR, Yang FC, Tseng PT, Tu YK, et al. Cognitive effects and acceptability of non-invasive brain stimulation on Alzheimer's disease and mild cognitive impairment: a component network meta-analysis. J Neurol Neurosurg Psychiatry. 2021; 92: 195-203.
[9] Cotelli M, Calabria M, Manenti R, Rosini S, Zanetti O, Cappa SF, et al. Improved language performance in Alzheimer disease following brain stimulation. J Neurol Neurosurg Psychiatry. 2011; 82: 794-7.

[10] Trebbastoni A, Raccah R, de Lena C, Zangen A, Inghilleri M. Repetitive deep transcranial magnetic stimulation improves verbal fluency and written language in a patient with primary progressive aphasia-logopenic variant (LPPA). Brain Stimul. 2013; 6: 545-53.

[11] Devi G, Voss HU, Levine D, Abrassart D, Heier L, Halper J, et al. Open-label, short-term, repetitive transcranial magnetic stimulation in patients with Alzheimer's disease with functional imaging correlates and literature review. Am J Alzheimers Dis Other Demen. 2014; 29: 248-55.

[12] Eliasova I, Anderkova L, Marecek R, Rektorova I. Non-invasive brain stimulation of the right inferior frontal gyrus may improve attention in early Alzheimer's disease: a pilot study. J Neurol Sci. 2014; 346: 318-22.

[13] Anderkova L, Eliasova I, Marecek R, Janousova E, Rektorova I. Distinct Pattern of Gray Matter Atrophy in Mild Alzheimer's Disease Impacts on Cognitive Outcomes of Noninvasive Brain Stimulation. J Alzheimers Dis. 2015; 48: 251-60.

[14] Drumond Marra HL, Myczkowski ML, Maia Memoria C, Arnaut D, Leite Ribeiro P, Sardinha Mansur CG, et al. Transcranial Magnetic Stimulation to Address Mild Cognitive Impairment in the Elderly: A Randomized Controlled Study. Behav Neurol. 2015; 2015: 287843.
[15] Padala PR, Padala KP, Lensing SY, Jackson AN, Hunter CR, Parkes CM, et al. Repetitive transcranial magnetic stimulation for apathy in mild cognitive impairment: A double-blind, randomized, sham-controlled, cross-over pilot study. Psychiatry Res. 2018; 261: 312-8.

[16] Zhao J, Li Z, Cong Y, Zhang J, Tan M, Zhang H, et al. Repetitive transcranial magnetic stimulation improves cognitive function of Alzheimer's disease patients. Oncotarget. 2017; 8: 33864-71.

[17] Turriziani P, Smirni D, Mangano GR, Zappala G, Giustiniani A, Cipolotti L, et al. Low-Frequency Repetitive Transcranial Magnetic Stimulation of the Right Dorsolateral Prefrontal Cortex Enhances Recognition Memory in Alzheimer's Disease. J Alzheimers Dis. 2019; 72: 613-22.

[18] Zhang F, Qin Y, Xie L, Zheng C, Huang X, Zhang M. High-frequency repetitive transcranial magnetic stimulation combined with cognitive training improves cognitive function and cortical metabolic ratios in Alzheimer's disease. J Neural Transm (Vienna). 2019; 126: 1081-94.

[19] Bagattini C, Zanni M, Barocco F, Caffarra P, Brignani D, Miniussi C, et al. Enhancing cognitive training effects in Alzheimer's disease: rTMS as an add-on treatment. Brain Stimul. 2020; 13: 1655-64.

[20] Rutherford G, Lithgow B, Moussavi Z. Short and Long-term Effects of rTMS Treatment on Alzheimer's Disease at Different Stages: A Pilot Study. J Exp Neurosci. 2015; 9: 43-51.

[21] Koch G, Bonni S, Pellicciari MC, Casula EP, Mancini M, Esposito R, et al.
Transcranial magnetic stimulation of the precuneus enhances memory and neural activity in prodromal Alzheimer's disease. Neuroimage. 2018; 169: 302-11.

[22] Weiler M, Stieger KC, Long JM, Rapp PR. Transcranial Magnetic Stimulation in Alzheimer's Disease: Are We Ready? eNeuro. 2020; 7.

[23] Mimura Y, Nishida H, Nakajima S, Tsugawa S, Morita S, Yoshida K, et al. Neurophysiological biomarkers using transcranial magnetic stimulation in Alzheimer's disease and mild cognitive impairment: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2021; 121: 47-59.

[24] Yuan TF, Li WG, Zhang C, Wei H, Sun S, Xu NJ, et al. Targeting neuroplasticity in patients with neurodegenerative diseases using brain stimulation techniques. Transl Neurodegener. 2020; 9: 44.

[25] Sorg C, Riedl V, Muhlau M, Calhoun VD, Eichele T, Laer L, et al. Selective changes of resting-state networks in individuals at risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2007; 104: 18760-5.

[26] Buckner RL, Sepulcre J, Talukdar T, Krienen FM, Liu H, Hedden T, et al. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci. 2009; 29: 1860-73.

[27] Wang L, Zang Y, He Y, Liang M, Zhang X, Tian L, et al. Changes in hippocampal connectivity in the early stages of Alzheimer's disease: evidence from resting state fMRI. Neuroimage. 2006; 31: 496-504.
[28] Zhou J, Greicius MD, Gennatas ED, Growdon ME, Jang JY, Rabinovici GD, et al. Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease. Brain. 2010; 133: 1352-67.

[29] Grieder M, Wang DJJ, Dierks T, Wahlund LO, Jann K. Default Mode Network Complexity and Cognitive Decline in Mild Alzheimer's Disease. Front Neurosci. 2018; 12: 770.

[30] Celone KA, Calhoun VD, Dickerson BC, Atri A, Chua EF, Miller SL, et al. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J Neurosci. 2006; 26: 10222-31.

[31] Agosta F, Pievani M, Geroldi C, Copetti M, Frisoni GB, Filippi M. Resting state fMRI in Alzheimer's disease: beyond the default mode network. Neurobiol Aging. 2012; 33: 1564-78.

[32] Lorenzi M, Beltramello A, Mercuri NB, Canu E, Zoccatelli G, Pizzini FB, et al. Effect of memantine on resting state default mode network activity in Alzheimer's disease. Drugs Aging. 2011; 28: 205-17.

[33] Sole-Padulles C, Bartres-Faz D, Llado A, Bosch B, Pena-Gomez C, Castellvi M, et al. Donepezil treatment stabilizes functional connectivity during resting state and brain activity during memory encoding in Alzheimer's disease. J Clin Psychopharmacol. 2013; 33: 199-205.

[34] Blautzik J, Keeser D, Paolini M, Kirsch V, Berman A, Coates U, et al. Functional connectivity increase in the default-mode network of patients with Alzheimer's
disease after long-term treatment with Galantamine. Eur Neuropsychopharmacol. 2016; 26: 602-13.

[35] Wang JX, Rogers LM, Gross EZ, Ryals AJ, Dokucu ME, Brandstatt KL, et al. Targeted enhancement of cortical-hippocampal brain networks and associative memory. Science. 2014; 345: 1054-7.

[36] Balderston NL, Roberts C, Beydler EM, Deng ZD, Radman T, Luber B, et al. A generalized workflow for conducting electric field-optimized, fMRI-guided, transcranial magnetic stimulation. Nat Protoc. 2020; 15: 3595-614.

[37] O'Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007; 62: 1208-16.

[38] Blumberger DM, Vila-Rodriguez F, Thorpe KE, Feffer K, Noda Y, Giacobbe P, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018; 391: 1683-92.

[39] Ge R, Downar J, Blumberger DM, Daskalakis ZJ, Vila-Rodriguez F. Functional connectivity of the anterior cingulate cortex predicts treatment outcome for rTMS in treatment-resistant depression at 3-month follow-up. Brain Stimul. 2020; 13: 206-14.

[40] Yan CG, Zang YF. DPARSF: A MATLAB Toolbox for "Pipeline" Data Analysis of Resting-State fMRI. Front Syst Neurosci. 2010; 4: 13.

[41] Song XW, Dong ZY, Long XY, Li SF, Zuo XN, Zhu CZ, et al. REST: a toolkit
for resting-state functional magnetic resonance imaging data processing. PLoS One. 2011; 6: e25031.

[42] Lee TW, Girolami M, Sejnowski TJ. Independent component analysis using an extended infomax algorithm for mixed subgaussian and supergaussian sources. Neural Comput. 1999; 11: 417-41.

[43] Himberg J, Hyvarinen A, Esposito F. Validating the independent components of neuroimaging time series via clustering and visualization. Neuroimage. 2004; 22: 1214-22.

[44] Liao W, Wu GR, Xu Q, Ji GJ, Zhang Z, Zang YF, et al. DynamicBC: a MATLAB toolbox for dynamic brain connectome analysis. Brain Connect. 2014; 4: 780-90.

[45] Hermiller MS, Karp E, Nilakantan AS, Voss JL. Episodic memory improvements due to noninvasive stimulation targeting the cortical-hippocampal network: A replication and extension experiment. Brain Behav. 2019; 9: e01393.

[46] Rutherford G, Gole R, Moussavi Z. rTMS as a Treatment of Alzheimer's Disease with and without Comorbidity of Depression: A Review. Neurosci J. 2013; 2013: 679389.

[47] Wang W, Bian Q, Zhao Y, Li X, Du J, Zhang G, et al. Reliability and validity of the Chinese version of the Patient Health Questionnaire (PHQ-9) in the general population. Gen Hosp Psychiatry. 2014; 36: 539-44.

[48] Levis B, Benedetti A, Thombs BD. Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data
meta-analysis. BMJ. 2019; 365: l1476.

[49] Li X, Qi G, Yu C, Lian G, Zheng H, Wu S, et al. Cortical plasticity is correlated with cognitive improvement in Alzheimer's disease patients after rTMS treatment. Brain Stimul. 2021; S1935-861X (21)00017-6.

[50] Rabey JM, Dobronevsky E. Repetitive transcranial magnetic stimulation (rTMS) combined with cognitive training is a safe and effective modality for the treatment of Alzheimer's disease: clinical experience. J Neural Transm (Vienna). 2016; 123: 1449-55.

[51] Sheline YI, Raichle ME. Resting state functional connectivity in preclinical Alzheimer's disease. Biol Psychiatry. 2013; 74: 340-7.

[52] Dillen KNH, Jacobs HIL, Kukolja J, Richter N, von Reutern B, Onur OA, et al. Functional Disintegration of the Default Mode Network in Prodromal Alzheimer's Disease. J Alzheimers Dis. 2017; 59: 169-87.

[53] Yildirim E, Soncu Buyukiscan E. Default Mode Network Connectivity in Alzheimers Disease. Turk Psikiyatri Derg. 2019; 30: 279-86.

[54] Lin Y, Jiang WJ, Shan PY, Lu M, Wang T, Li RH, et al. The role of repetitive transcranial magnetic stimulation (rTMS) in the treatment of cognitive impairment in patients with Alzheimer's disease: A systematic review and meta-analysis. J Neurol Sci. 2019; 398: 184-91.

[55] Cui H, Ren R, Lin G, Zou Y, Jiang L, Wei Z, et al. Repetitive Transcranial Magnetic Stimulation Induced Hypoconnectivity Within the Default Mode Network
Yields Cognitive Improvements in Amnestic Mild Cognitive Impairment: A Randomized Controlled Study. J Alzheimers Dis. 2019; 69: 1137-51.

[56] Holczer A, Nemeth VL, Vekony T, Vecsei L, Klivenyi P, Must A. Non-invasive Brain Stimulation in Alzheimer's Disease and Mild Cognitive Impairment-A State-of-the-Art Review on Methodological Characteristics and Stimulation Parameters. Front Hum Neurosci. 2020; 14: 179.
| Characteristic       | rTMS group (n=31) | sham group (n=27) | p-value |
|---------------------|-------------------|-------------------|---------|
| Age (years)         | 70.39 ± 8.47      | 71.67 ± 7.16      | 0.540   |
| Female (%)          | 71.0%             | 74.1%             | 0.792   |
| Education (years)   | 7.06 ± 5.51       | 6.63 ± 4.99       | 0.755   |
| Medication (%)      | 67.7%             | 70.4%             | 0.829   |
| MMSE                | 14.36 ± 6.94      | 13.74 ± 7.16      | 0.742   |
| CDR                 | 1.13 ± 0.56       | 1.17 ± 0.54       | 0.796   |
| ADL                 | 29.07 ± 7.54      | 32.26 ± 9.73      | 0.165   |
| PQH-9               | 1.81 ± 3.35       | 1.41 ± 2.06       | 0.594   |
| PVLT                |                   |                   |         |
| Immediate           | 12.45 ±9.16       | 10.30 ± 9.52      | 0.384   |
| Short Delay         | 2.52 ± 3.27       | 2.30 ± 3.62       | 0.809   |
| Long Delay          | 1.61 ± 3.09       | 1.07 ± 2.18       | 0.453   |

Notes: Means ± standard deviation tested by two-sample t-tests (2-tailed).
Abbreviations: MMSE: Mini-Mental State Examination; CDR: Clinical Dementia Rating; ADL: Activities of Daily Living scale; PHQ-9: Patient Health Questionnaire-9; PVLT: 12-Word Philadelphia Verbal Learning Test.
Table 2. Baseline characteristics of Alzheimer’s disease patients and the improvements after the rTMS (Baseline, Immediate after treatment and Twelve weeks follow-up)

| Characteristic | rTMS group (n=31) | p-value | sham group (n=27) | p-value |
|---------------|------------------|---------|------------------|---------|
|               | Baseline [B] | Immediate | Twelve weeks follow-up [T] | vs. vs. | Baseline [B] | Immediate | Twelve weeks follow-up [T] | vs. vs. |
| MMSE          | 14.36 ± 6.94 | 15.52 ± 7.23 | 13.82 ± 7.82 | 0.000** 0.892 | 13.74 ± 7.16 | 14.30 ± 7.76 | 14.75 ± 7.55 | 0.273 0.406 |
| CDR           | 1.13 ± 0.56 | 1.11 ± 0.57 | 1.14 ± 0.58 | 0.768 0.815 | 1.17 ± 0.54 | 1.19 ± 0.57 | 1.05 ± 0.54 | 0.713 0.804 |
| ADL           | 29.07 ± 7.54 | 29.36 ± 8.00 | 31.50 ± 9.48 | 0.53 0.126 | 32.26 ± 9.73 | 32.44 ± 9.36 | 30.35 ± 10.24 | 0.811 0.383 |
| PQH-9         | 1.81 ± 3.35 | 2.32 ± 4.50 | 2.36 ± 4.48 | 0.29 0.339 | 1.41 ± 2.06 | 0.70 ± 0.90 | 1.65 ± 2.60 | 0.103 0.212 |
| PVLT Immediate | 12.45 ± 9.16 | 15.58 ± 10.27 | 13.18 ± 10.02 | <0.001*** 0.129 | 10.30 ± 9.52 | 11.56 ± 11.03 | 13.65 ± 11.65 | 0.124 0.340 |
| Short Delay   | 2.52 ± 3.27 | 3.38 ± 3.68 | 3.77 ± 4.95 | 0.044* 0.064 | 2.30 ± 3.62 | 2.48 ± 3.25 | 3.20 ± 3.74 | 0.686 0.137 |
| Long Delay    | 1.61 ± 3.09 | 2.07 ± 3.48 | 2.18 ± 4.59 | 0.080 0.126 | 1.07 ± 2.18 | 1.63 ± 3.21 | 1.50 ± 2.80 | 0.146 0.748 |

Notes: Means ± standard deviation tested by paired t-tests (2-tailed).

Twelve weeks follow-up was completed for 22 (71%) in the rTMS group and 20 (74%) in the sham group.

*p<0.05; **p<0.01; ***p<0.001.

Abbreviations: MMSE: Mini-Mental State Examination; CDR: Clinical Dementia Rating; ADL: Activities of Daily Living scale; PHQ-9: Patient Health Questionnaire-9; PVLT: 12-Word Philadelphia Verbal Learning Test.
Fig. 1. (A) Overview of the DMN in all patients based on the group ICA. (B) Differences in the dFC magnitude of the DMN at each timeline of the experiment (baseline, immediately after, 12-week follow-up after the treatment). (C) A scatter plot shows the correlation between changes of the MMSE and changes of the dFC magnitude of the DMN immediately after 2 weeks of treatment. Abbreviations: DMN: default mode network; dFC: dynamic functional connectivity; MMSE: Mini-Mental State Examination; T0: baseline; T1: immediately after the treatment; T2: 12-week follow-up after the treatment; L: left; R: right.
Figures

(A) Overview of the DMN in all patients based on the group ICA. (B) Differences in the dFC magnitude of the DMN at each timeline of the experiment (baseline, immediately after, 12-week follow-up after the treatment). (C) A scatter plot shows the correlation between changes of the MMSE and changes of the dFC magnitude of the DMN immediately after 2 weeks of treatment. Abbreviations: DMN: default mode network; dFC: dynamic functional connectivity; MMSE: Mini-Mental State Examination; T0: baseline; T1: immediately after the treatment; T2: 12-week follow-up after the treatment; L: left; R: right.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- AppendixA.Supplementarydata.docx